Zentiva to be unifying brand for Sanofi-Aventis' European generics business

French drug major Sanofi-Aventis is says that all of its European generic pharmaceuticals businesses will now operate under the unified brand name Zentiva. The re-branding of its generic operations in Western Europe signals the group’s intention to create a dynamic, growing business providing access to modern, high quality affordable medicines to 800 million people across the whole of Europe, Russia and Turkey.

By unifying the group’s generic activities under the Zentiva brand Sanofi-Aventis says it has created the third largest generics company in the European market and, more importantly, the fastest growing. The group’s total sales of generic drugs were 1.53 billion euros ($2.17 billion) in 2010.

Generics crucial to global plans